Evidence map›Paper›PMID 33072436›Full record

ArticlePeerJ2020

A novel dual MEK/PDK1 inhibitor 9za retards the cell cycle at G

Rangru Liu, Zutao Yu, Zhuo Chen, Danqi Liu, Fengying Huang, Qianbin Li, Gaoyun Hu, Xinan Yi, Xi Li, Honghao Zhou and 1 more

Open access · goldAbstract read
In one paragraph

Article in PeerJ, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Rangru LiuKey Laboratory of Tropical Translational Medicine of the Ministry of Education & Hainan Key Laboratory for Research and Development of Tropical Herbs, School of Pharmacy, Hainan Medical University, Haikou, People's Republic of China.
Zutao YuDepartment of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, People's Republic of China.
Zhuo ChenDepartment of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, People's Republic of China.
Danqi LiuDepartment of Pharmacy, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Fengying HuangKey Laboratory of Tropical Diseases and Translational Medicine of the Ministry of Education & Hainan Provincial Key Laboratory of Tropical Medicine, Hainan Medical University, Haikou, People's Republic of China.
Qianbin LiDepartment of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, People's Republic of China.
Gaoyun HuDepartment of Medicinal Chemistry, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, People's Republic of China.
Xinan YiThe United Laboratory for Neurosciences of Hainan Medical University and the Fourth Military Medical University, Haikou, People's Republic of China.
Xi LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Honghao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Zhaoqian LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Central South University · CNHainan Medical University · CNAir Force Medical University · CNXiangya Hospital Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA novel dual MEK/PDK1 inhibitor named 9za has been synthesized by our research team. Preliminary study showed that 9za possessed potent cytotoxicity and proapoptosis in non-small cell lung cancer (NSCLC) cells. Nevertheless, the precise underlying mechanism is vague.

methodsIn this work, we adopted the MTT assay, the Cell Cycle Detection Kit, and the JC-1 staining assay to detect the cell viability, the cell cycle distribution and the mitochondrial membrane potential (MMP), respectively. Cell apoptosis was measured by the morphology observation under a light microscope, Annexin V-FITC/propidium iodide (PI) apoptosis detection and the colorimetric TUNEL assay. Western blot was used to monitor the cell cycle-, apoptosis-related proteins and relevant proteins involved in the signaling pathways.

resultsThe MTT assay demonstrated that 9za sharply decreased the viability of NSCLC cells. Cell cycle analysis revealed that low concentrations of 9za arrested the cell cycle at the G

Indexed as

9zaA dual MEK/PDK1 inhibitorCell cycle arrestCytotoxicityMitochondrial apoptosisNon-small cell lung cancer

Identifiers

PMID33072436
PMCPMC7537639
OpenAlexW3089958183

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.